

ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)

Adelaide, Australia

Date: 14 November 2017

Release: Immediate

Topic: Availability of Ellex SPP Offer Documents

---



**Adelaide, Australia, 14 November 2017** – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, is pleased to provide shareholders with this update on the status of the Ellex Share Purchase offer documents.

The Ellex Share Purchase Plan Terms and Conditions will be lodged with ASX later today. Eligible shareholders will be sent a copy of the SPP terms and conditions and an accompanying personalised application form (together with “SPP documents”). The SPP documents will be despatched, and available later this afternoon.

The SPP documents will be made available to eligible shareholders by the following methods:

- The documents will be sent by post later today to all eligible shareholders. Ellex has arranged for the documents to be sent by priority post.
- Shareholders who have previously registered to receive company correspondence electronically (e.g. annual report, notices of meeting etc.) should receive an email later this afternoon with links to retrieve the documents electronically.
- Shareholders with a Computershare ‘Investor Centre’ login will be able to login to their account online and download the documents.

Ellex shareholders should be aware that their personalised application form will be made available by the methods described above and that Ellex will not be emailing individual personalised application forms to shareholders.

---

## ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

**For additional information about Ellex and its products, please visit [www.ellex.com](http://www.ellex.com)**

---

### **For further information on Ellex please contact:**

Tom Spurling, CEO  
Ellex Medical Lasers Limited  
3 Second Avenue, Mawson Lakes, SA, 5095  
W +61 8 7074 8293 | M +61 417 818 658  
[tspurling@ellex.com](mailto:tspurling@ellex.com)

Maria Maieli, CFO & Company Secretary  
Ellex Medical Lasers Limited  
3 Second Avenue, Mawson Lakes, SA, 5095  
W +61 8 7074 8200  
[mmaieli@ellex.com](mailto:mmaieli@ellex.com)